Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness.
The aim of the second part of this review is to examine optimal neuromuscular management strategies that can be used by clinicians to reduce the risk of residual paralysis in the early postoperative period. Current evidence has demonstrated that frequently used clinical tests of neuromuscular function (such as head lift or hand grip) cannot reliably exclude the presence of residual paralysis. When qualitative (visual or tactile) neuromuscular monitoring is used (train-of-four [TOF], double-burst, or tetanic stimulation patterns), clinicians often are unable to detect fade when TOF ratios are between 0.6 and 1.0. Furthermore, the effect of qualitative monitoring on postoperative residual paralysis remains controversial. In contrast, there is strong evidence that acceleromyography (quantitative) monitoring improves detection of small degrees (TOF ratios >0.6) of residual blockade. The use of intermediate-acting neuromuscular blocking drugs (NMBDs) can reduce, but do not eliminate, the risk of residual paralysis when compared with long-acting NMBDs. In addition, complete recovery of neuromuscular function is more likely when anticholinesterases are administered early (>15-20 minutes before tracheal extubation) and at a shallower depth of block (TOF count of 4). Finally, the recent development of rapid-onset, short-acting NMBDs and selective neuromuscular reversal drugs that can effectively antagonize deep levels of blockade may provide clinicians with novel pharmacologic approaches for the prevention of postoperative residual weakness and its associated complications.
Brull
Sorin J
SJ
Department of Anesthesiology, Mayo Clinic College of Medicine, 4500 San Pablo Rd., Jacksonville, FL 32224, USA. SJBrull@me.com
Murphy
Glenn S
GS
D004558:Electric Stimulation; D006801:Humans; D008991:Monitoring, Physiologic / Q000295:instrumentation; D009119:Muscle Contraction / Q000187:drug effects; D018908:Muscle Weakness / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D019148:Neuromuscular Blockade / Q000009:adverse effects* / Q000379:methods; D009467:Neuromuscular Depolarizing Agents / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D011183:Postoperative Complications / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D009626:Terminology as Topic
D009467:Neuromuscular Depolarizing Agents